client logo

Coagulopathies & arterial/venous thrombosis in COVID patients: an OMOP dataset

Dataset
Version: 1.0.0
Hosp patients admitted during COVID pandemic with coagulopathies including venous thromboembolic events & bleeds. Granular condition, multi-morbidity, interventions & treatments. Serial physiology, blood biomarkers, ITU spells, outcome. Deeply phenotyped.

Summary

Citation:
Coagulopathies & arterial/venous thrombosis in COVID patients: an OMOP dataset

Documentation

Description:
In December 2019, the first case of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) was described and by March 2020, the World Health Organization had declared the disease (Coronavirus disease 2019, COVID-19) a pandemic. Whilst respiratory symptoms are the fundamental feature of the disease, evidence indicates that the disease is associated with coagulation dysfunction which predisposes patients to an increased risk of both venous and arterial thromboembolism (TE) and potentially increased mortality risk as a consequence. Biomarkers associated with TE (D-dimers) are often raised in people with COVID but without clear evidence of TE. It is important to understand who is at most risk of TE, to manage disease effectively. This dataset (in OMOP) describes patients with and without COVID who were admitted to UHB including all those with and without TE. PIONEER geography: The West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix. Birmingham was hard hit by all COVID waves and University Hospitals Birmingham NHS Foundation Trust (UHB) had >8000 COVID admissions by the end of December 2020. EHR. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & an expanded 250 ITU bed capacity during COVID. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”. Scope: All patients admitted during the first wave of the COVID-19, both with and without COVID. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes. Serial, structured data pertaining to acute care process (timings, staff grades, specialty review, wards), presenting complaint, SARS-CoV-2 swab result, diagnosis of TE, clotting parameters, D-Dimers, acuity, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations), all blood results, imaging reports, all prescribed & administered treatments (fluids, antibiotics, inotropes, vasopressors, organ support), all outcomes. Available supplementary data: Matched controls; ambulance, synthetic data. Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.
Is Part Of:
Part of the DECOVID dataset

Coverage

Spatial:
United Kingdom, England, West Midlands
Typical Age Range:
18-110
Follow Up:
0 - 6 MONTHS
Physical Sample Availability:
NOT AVAILABLE
Pathway:
Data focuses on in-patient stay in hospital during the acute episode but can be supplemented on request to include previous and subsequent hospital contacts (including outpatient appointments) and ambulance, 111, 999 data. Data includes those with and without COVID admitted during the first wave of the COVID pandemic.

Provenance

Origin

Purposes:
OTHER
Sources:
EPR
Collection Situations:
  • COMMUNITY
  • IN-PATIENTS
  • OUTPATIENTS

Temporal

Accrual Periodicity:
STATIC
Distribution Release Date:
2020-12-08
Start Date:
2020-01-01
End Date:
2020-09-09
Time Lag:
LESS 1 WEEK

Accessibility

Access

Access Service:
Trusted Research Environments (TRE) are built using Microsoft Azure services and hosted in the UK to provide research teams a safe, secure and agile environment which allows users to quickly analyse, interpret and form an enriched view of primary care information through a range of integrated datasets. Health data collated from multiple sources is ingested into a secure data lake which will then allow subsets of data to be made available to research teams on approval of a data request. Once approved a customer specific TRE is made available with a standard set of leading analytical tools from Microsoft including Azure Databricks, Azure Machine Learning, Azure SQL and Azure Synapse (for large-scale data warehouses). Specific tools can be provided at an additional cost over the standard platform data access charge and the PIONEER team will work with you to determine your exact needs. Access to the TRE is managed using the latest virtual desktop technology to provide a safe and secure end-user experience. By utilising leading edge design PIONEER are able to create TREs rapidly to enable us to service any customer requirement.
Access Request Cost:
www.pioneerdatahub.co.uk/data/data-services-costs/
Delivery Lead Time:
1-2 MONTHS
Jurisdictions:
GB
Data Controller:
University Hospitals Birmingham NHS Foundation Trust
Data Processor:
NOT APPLICABLE

Usage

Data Use Limitations:
RESEARCH USE ONLY
Data Use Requirements:
PROJECT SPECIFIC RESTRICTIONS
Resource Creators:
  • This publication uses data from PIONEER
  • an ethically approved database and analytical environment (East Midlands Derby Research Ethics 20/EM/0158)
Is Referenced By:
Sawlani, V., Scotton, S., Nader, K., Jen, J. P., Patel, M., Gokani, K., Denno, P., Thaller, M., Englezou, C., Janjua, U., Bowen, M., Hoskote, C., Veenith, T., Hassan-Smith, G., & Jacob, S. (2021). COVID-19-related intracranial imaging findings: a large single-centre experience. Clinical radiology, 76(2), 108–116. https://doi.org/10.1016/j.crad.2020.09.002

Format and Standards

Vocabulary Encoding Schemes:
  • ICD10
  • SNOMED CT
Conforms To:
OMOP
Languages:
en
Formats:
SQL

Observations

Statistical Population
Population Description
Population Size
Measured Property
Observation Date
Events
50,899 patients including Coagulopathy and Non-Coagulopathy control group.
50,899
Count
2020-12-09